^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

cordycepin (OVI-123)

i
Other names: NSC 63984, OVI-123
Associations
Trials
Company:
OncoVista
Drug class:
RNA synthesis inhibitor
Associations
Trials
9d
Differential Effects of Curcumin and Cordycepin on Oral Squamous Cell Carcinoma Cells: ROS-Mediated Cytotoxicity and Real-Time Morphological Analysis. (PubMed, Molecules)
The combination treatment (CC) largely reflected Cu-driven morphological and functional changes, with Co coexisting without counteracting Cu's effects. Taken together, these findings reveal compound-specific mechanisms of action for Cu and Co in OSCC therapy.
Journal
|
CASP3 (Caspase 3) • CASP7 (Caspase 7)
|
cordycepin (OVI-123)
15d
Efficient production of cordycepin in engineered Saccharomyces cerevisiae. (PubMed, Bioresour Technol)
In fed-batch fermentation, SCC7 achieved 6972.8 mg/L COR in a 6 L bioreactor, representing the highest COR titer reported in S. cerevisiae to date. In conclusion, this study establishes an efficient yeast platform for COR production and provides a useful reference for biosynthesis of other bioactive nucleosides.
Journal
|
PGK1 (Phosphoglycerate Kinase 1)
|
cordycepin (OVI-123)
17d
Sex determining region Y box protein 2 (SOX2) expression, alteration, regulation and its diagnostics, prognostics and therapeutics in lung cancer. (PubMed, Discov Oncol)
Given its oncogenic potential, this study aimed to investigate the potential of SOX2 as a biomarker and evaluate the inhibitory effects of cordycepin (CD), a natural compound, on SOX2-driven oncogenic phenotypes in lung cancer...Moreover, overexpression of SOX2 promoted lung cancer cell growth, migration, and invasion, while CD, a natural product originally from the traditional Chinese medicine Cordyceps sinensis (BerK.), suppressed SOX2-mediated progression, including the growth, migration, and invasion of lung cancer. Taken together, these results implied that SOX2 is a potential biomarker for diagnostics, prognostics, and therapeutics for lung cancer, including LUAD and LUSC.
Journal
|
SOX2
|
cordycepin (OVI-123)
1m
Mushrooms as potent autophagy modulators in cancer therapy: Current evidence and therapeutic prospects. (PubMed, Cancer Pathog Ther)
The review lists over 18 mushroom species (e.g., Ganoderma lucidum, Cordyceps, Phellinus) and 28 bioactive compounds (such as Ganoderic acid DM, Cordycepin, Hispidin) that affect autophagy, demonstrating efficacy against 15 cancer types, including colorectal, lung, breast, and liver cancers...The context-dependent effects of autophagy, along with the limited clinical evidence, present considerable challenges. Future clinical trials must focus on developing standardized extracts and personalized approaches to effectively translate this potential into clinical practice.
Review • Journal
|
mTOR (Mechanistic target of rapamycin kinase) • BECN1 (Beclin 1)
|
cordycepin (OVI-123)
2ms
Exploring the behavioural and biochemical effects of cordycepin in PTSD-like behaviour using an early life stress mouse model. (PubMed, Biochem Biophys Res Commun)
Mice exhibiting PTSD-like behaviour were treated with fluoxetine (FLU, 10 mg/kg), an antidepressant drug, and COR (10 and 50 mg/kg). COR demonstrated a dose-dependent response with 50 mg/kg showing consistent improvement in both behavioural and biochemical parameters. Overall, COR exhibited promising activity in this model and may serve as a potential natural therapeutic strategy to investigate for the management of PTSD in clinics.
Preclinical • Journal
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL1B (Interleukin 1, beta) • NLRP3 (NLR Family Pyrin Domain Containing 3)
|
fluoxetine • cordycepin (OVI-123)
2ms
Mechanistic insights into cordycepin-enhanced CTLA-4 blockade efficacy via Eubacterium rectale-mediated immunomodulation in colon cancer. (PubMed, Int Immunopharmacol)
Non-targeted metabolomics analysis using LC-MS identified specific activation of the histidine metabolism pathway, with elevated levels of the key metabolite Cetirizine N-Oxide potentially contributing to enhanced immune activity. Mechanistic studies further revealed that the triple therapy suppresses the activity of the Bcl6 regulatory network, thereby reducing the immunosuppressive function of Tregs and destroying the immunosuppressive interplay between myeloid immune cells and Tregs. These results demonstrate a promising "microbiome-immune" dual-targeting strategy for colon cancer with clinical translational potential.
Journal
|
BCL6 (B-cell CLL/lymphoma 6) • CD4 (CD4 Molecule)
|
cordycepin (OVI-123)
2ms
Cordycepin inhibits human extravillous trophoblast invasion by suppressing snail-mediated MMP2 expression. (PubMed, Tissue Cell)
Functionally, COR treatment inhibited EVT cell invasion, and this effect was mediated by MMP2 downregulation. These findings provide new insights into the molecular mechanisms by which COR regulates EVT cell invasiveness and highlight the potential implications of COR as a health supplement during pregnancy.
Journal
|
MMP2 (Matrix metallopeptidase 2)
|
cordycepin (OVI-123)
3ms
Combination treatment of cordycepin and radiation induces apoptosis accompanied by protective autophagy in TM3 mouse Leydig progenitor cells. (PubMed, J Food Drug Anal)
Although apoptosis is eventually induced in TM3 cells, protective autophagy is also activated to mitigate the cytotoxic impact of the combination treatment. This finding may provide a reference for the development of safe therapeutic regimen for Leydig cell tumors.
Preclinical • Journal
|
ATG5 (Autophagy Related 5) • ATG12 (Autophagy Related 12) • BECN1 (Beclin 1)
|
cordycepin (OVI-123)
3ms
Cordycepin in cancer therapy: A bibliometric analysis and review of mechanisms. (PubMed, J Food Drug Anal)
Future research should prioritize pharmacokinetic characterization, investigation of combinatorial therapeutic strategies, and pathways toward clinical translation. Intracellular exposure appears to be shaped by two complementary axes: interference with 3'end polyadenylation and ENT1/ENT2-mediated uptake with ADA-catalyzed deamination.
Review • Journal
|
SLC29A1 (Solute Carrier Family 29 Member 1) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
|
cordycepin (OVI-123)
3ms
Evaluation of the Effect of Cordycepin on CD8+ Lymphocytopenia in Patients With Solid Tumors (clinicaltrials.gov)
P2, N=127, Recruiting, Second Affiliated Hospital of Soochow University | Not yet recruiting --> Recruiting
Enrollment open
|
CD8 (cluster of differentiation 8)
|
cordycepin (OVI-123)
3ms
Cordycepin suppresses the progression of multiple myeloma by inducing ferroptosis through upregulating CLEC2. (PubMed, Cytotechnology)
Collectively, COR inhibited MM progression by inducing ferroptosis through upregulating CLEC2. The online version contains supplementary material available at 10.1007/s10616-025-00886-5.
Journal
|
HIF1A (Hypoxia inducible factor 1, alpha subunit) • GPX4 (Glutathione Peroxidase 4) • ACSL4 (Acyl-CoA Synthetase Long Chain Family Member 4) • SLC7A11 (Solute Carrier Family 7 Member 11)
|
cordycepin (OVI-123)
4ms
An Immunomodulatory Mushroom, Cordyceps militaris, and Its Constituents: A Review of In Vitro/In Vivo Studies and Clinical Trials. (PubMed, Phytother Res)
They enhance innate and cell-mediated adaptive immunity not only under normal conditions but also in immunosuppressed states induced by cyclophosphamide, interleukin-4, tumor culture supernatant, methotrexate, cancer cell-line-xenografts, influenza virus, and severe acute respiratory syndrome coronavirus 2. This study reviewed recent and notable literature evaluating the immunomodulatory potentials of CM extract, cordycepin, and polysaccharides. In vitro, in vivo, and clinical trial results indicate that CM is safe for administration and shows promise for developing functional foods having various efficacies such as immunomodulation, anti-tumor, and neuroprotection.
Preclinical • Review • Journal
|
IL4 (Interleukin 4)
|
cyclophosphamide • methotrexate • cordycepin (OVI-123)